Lantern Pharma Inc. cash flow to debt ratio of -19.96% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Lantern Pharma Inc.'s free cash flow has increased -12.04% from $-17.83M last year to $-15.68M, signaling increasing performance

Lantern Pharma Inc.'s debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Lantern Pharma Inc.'s debt has increased relative to shareholder equity from 0.01 last year to 0.02 today, signaling weakened financials

Lantern Pharma Inc. has negative EBITDA, making leverage ratio unreliable

Lantern Pharma Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Lantern Pharma Inc. has insufficient data to evaluate this check.

Lantern Pharma Inc.'s short-term assets of $10.80M exceed its short-term liabilities of $4.50M

Lantern Pharma Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Lantern Pharma Inc.'s return on equity of -198.35%, is lower than 15.00%, indicating bad performance

Lantern Pharma Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Lantern Pharma Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Lantern Pharma Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Lantern Pharma Inc. has negative free cash flow, indicating cash burn

Lantern Pharma Inc.'s yearly earnings has increased -17.62% since last year from $-20.78M to $-17.12M, signaling increasing performance

Lantern Pharma Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -473.92% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Lantern Pharma Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Lantern Pharma Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Lantern Pharma Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Lantern Pharma Inc. is undervalued relative to its fair value price of 63.15 based on Discounted Cash Flow model

Lantern Pharma Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lantern Pharma Inc. is undervalued relative to its fair value price of 374.83 based on EBITDA multiple model

Lantern Pharma Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Lantern Pharma Inc. has insufficient data to evaluate this check.

Lantern Pharma Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lantern Pharma Inc. has a price-to-book ratio of 10.03x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Lantern Pharma Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue